Beta%2525252525252525252525252525252525252525252525252520blockers

# Beta Blockers ## Overview Beta-adrenergic blocking agents (beta-blockers) competitively inhibit the binding of catecholamines (epinephrine and norepinephrine) to beta-adrenergic receptors. This results in decreased heart rate, myocardial contractility, and blood pressure. Selectivity for beta-1 (primarily in the heart) or non-selective blockade of beta-1 and beta-2 (lungs, vasculature) receptors exists. Some beta-blockers also possess alpha-blocking activity, leading to additional vasodilation. ## Primary Indications * Hypertension * Angina pectoris * Myocardial infarction (post-MI management) * Heart failure (certain agents) * Arrhythmias (e.g., supraventricular tachycardia, atrial fibrillation rate control) * Migraine prophylaxis * Hypertrophic obstructive cardiomyopathy * Thyrotoxicosis symptoms ## Adult Dosing Dosing is highly variable depending on the specific agent, indication, and patient response. Titration is typically required. * **Hypertension:** * Atenolol: 25-100 mg once daily. Max: 100 mg/day. * Metoprolol tartrate: 25-100 mg twice daily. Max: 400 mg/day. * Metoprolol succinate: 25-200 mg once daily. Max: 200 mg/day. * Propranolol: 40-160 mg twice daily. Max: 640 mg/day. * Carvedilol: 3.125-25 mg twice daily. Max: 50 mg twice daily (or 80 mg twice daily in severe heart failure). * Labetalol: 100-400 mg twice daily. Max: 2400 mg/day. * Nebivolol: 5 mg once daily. Max: 40 mg/day. * **Heart Failure (with reduced ejection fraction):** * Bisoprolol: Start 1.25 mg once daily, titrate up to target dose of 10 mg once daily. * Carvedilol: Start 3.125 mg twice daily, titrate up to target dose of 25 mg twice daily (or 50 mg twice daily if weight > 85 kg). * Metoprolol succinate: Start 25 mg once daily, titrate up to target dose of 200 mg once daily. * **Post-Myocardial Infarction:** * Metoprolol tartrate: 50-100 mg every 6-12 hours, started within 24 hours of MI. * Propranolol: 40-80 mg every 6-8 hours. * Carvedilol: 6.25 mg twice daily, titrate up to 12.5 mg twice daily, then 25 mg twice daily. ## Pediatric Dosing Established pediatric dosing is limited and often based on adult guidelines, weight-based calculations, and clinical judgment. Dosing should be individualized and guided by local protocols. * **Hypertension:** Dosing varies significantly by age and specific beta-blocker. For example, propranolol may be initiated at 0.5-1 mg/kg/day divided every 6-8 hours. Maximum doses are typically higher than in children. * **Tachyarrhythmias:** Similar variability exists. ## Dose Adjustments * **Renal Impairment:** Doses of renally eliminated beta-blockers (e.g., atenolol, nadolol) require adjustment. Metoprolol and propranolol also require caution. * **Hepatic Impairment:** Doses of hepatically metabolized beta-blockers (e.g., propranolol, metoprolol) may require reduction. ## Contraindications * Severe bradycardia * Heart block (second- or third-degree, without a pacemaker) * Cardiogenic shock * Decompensated heart failure * Sick sinus syndrome * Asthma or severe COPD (especially with non-selective beta-blockers) * Prinzmetal's angina * Raynaud's phenomenon (caution) ## Adverse Effects * Bradycardia, hypotension, dizziness, fatigue * Cold extremities * Bronchospasm (non-selective agents) * Masking of hypoglycemia symptoms (except sweating) * Erectile dysfunction * Depression, nightmares * Gastrointestinal upset (nausea, diarrhea) * Abrupt discontinuation can lead to rebound hypertension, angina, or MI. ## Key Drug Interactions * **Calcium Channel Blockers (e.g., verapamil, diltiazem):** Additive negative chronotropic and inotropic effects, increased risk of bradycardia and heart block. * **Digoxin:** Increased risk of bradycardia. * **Insulin/Oral Hypoglycemics:** Beta-blockers can mask tachycardia associated with hypoglycemia; caution in diabetics. * **CYP450 Inhibitors/Inducers:** May alter the metabolism of certain beta-blockers (e.g., metoprolol, propranolol). * **Alpha-blockers (e.g., prazosin):** Increased risk of orthostatic hypotension. * **Nonsteroidal Anti-inflammatory Drugs (NSAIDs):** May reduce antihypertensive effects. ## Monitoring * Blood pressure and heart rate * Electrocardiogram (ECG) for heart block or bradycardia * Signs and symptoms of heart failure (weight gain, edema, dyspnea) * Blood glucose levels in diabetic patients * Renal and hepatic function (periodically) * Signs of peripheral perfusion ## Clinical Pearls * Initiate beta-blockers at low doses and titrate slowly, especially in elderly patients or those with heart failure. * Avoid abrupt discontinuation; taper dose over 1-2 weeks to prevent rebound effects. * Non-selective beta-blockers should be used with extreme caution or avoided in patients with reactive airway disease. * Beta-1 selective agents may be preferred in patients with mild respiratory disease, but caution is still advised. * Carvedilol and labetalol have alpha-blocking activity, which can be beneficial in hypertension and heart failure due to vasodilation. * In heart failure, beta-blockers should be initiated once the patient is euvolemic and symptoms of decompensation are controlled. **Disclaimer:** This information is intended for healthcare professionals and does not replace comprehensive drug compendia or current prescribing information. Always consult the most up-to-date drug monograph for complete details and specific patient considerations.